Optipharm Inc.

Cheongju, South Korea

Optipharm Inc.

Cheongju, South Korea
SEARCH FILTERS
Time filter
Source Type

There are provided an information offering method for diagnosing breast cancer comprising: (a) separating total RNA from a cell obtained from a tissue or blood of a suspected cancer patient; (b) synthesizing a cDNA from the separated total RNA; (c) performing a real-time PCR with the synthesized cDNA by using primer pair mix and probe mix that can amplify human epidermal growth factor receptor 2 (HER2); wherein, the primer pair mix that can amplify human epidermal growth factor receptor 2 (HER2) are described as SEQ ID Nos.:1 and 2, 3 and 4, and 6 and 7 and the probe mix are described as SEQ ID Nos.: 5, 8, and 9.


Wang H.Y.,Optipharm Inc. | Uh Y.,Yonsei University | Kim S.,Yonsei University | Lee H.,Yonsei University
Clinical Microbiology and Infection | Year: 2016

Objectives: Rapid and accurate identification of the causative pathogens of bloodstream infections (BSIs) is crucial for initiating appropriate antimicrobial therapy, which decreases the related morbidity and mortality rates. The aim of this study was to evaluate the usefulness of a newly developed multiplexed, bead-based bioassay system, the Quantamatrix Multiplexed Assay Platform (QMAP) system, obtained directly from blood culture bottles, to simultaneously detect the presence of bacteria and identify the genes for antibiotic resistance. Methods: The QMAP system was used to evaluate 619 blood culture bottles from patients with BSIs and to compare the results of conventional culture methods. Results: Using conventional bacterial cultures as the reference standard, the sensitivity, specificity, positive predictive value, and negative predictive value of the QMAP system for detection of bacterial pathogens in positive blood culture (PBC) samples were 99.8% (n = 592, 95% CI 0.9852-1.000, p <0.001), 100% (95% CI 0.983-1.000, p <0.001), 100% (95% CI 0.9922-1.000, p <0.001), and 99.5% (95% CI 0.9695-1.000, p <0.001), respectively. In addition, sensitivity and specificity of the QMAP system for identification of the genes for antibiotic resistance were 99.4% (n = 158, 95% CI 0.9617-0.9999, p <0.009) and 99.6% (95% CI 0.9763-0.9999, p <0.0001), respectively. Conclusions: Obtaining results using the QMAP system takes about 3 hr, while culture methods can take 48-72 hr. Therefore, analysis using the QMAP system is rapid and reliable for characterizing causative pathogens in BSIs. © 2016 European Society of Clinical Microbiology and Infectious Diseases.


Wang H.-Y.,Optipharm Inc. | Uh Y.,Yonsei University | Kim S.,Yonsei University | Shim T.-S.,University of Ulsan | Lee H.,Yonsei University
International Journal of Infectious Diseases | Year: 2017

Background The differentiation of Mycobacterium tuberculosis complex (MTBC) from non-tuberculous mycobacteria (NTM) is of primary importance for infection control and the selection of anti-tuberculosis drugs. Up to date data on rifampicin (RIF)-resistant tuberculosis (TB) is essential for the early management of multidrug-resistant TB. The aim of this study was to evaluate the usefulness of a newly developed multiplexed, bead-based bioassay (Quantamatrix Multiplexed Assay Platform, QMAP) for the rapid differentiation of 23 Mycobacterium species including MTBC and RIF-resistant strains. Methods A total of 314 clinical Mycobacterium isolates cultured from respiratory specimens were used in this study. Results The sensitivity and specificity of the QMAP system for Mycobacterium species were 100% (95% CI 99.15–100%, p < 0.0001) and 97.8% (95% CI 91.86–99.87%, p < 0.0001), respectively. The results of conventional drug susceptibility testing and the QMAP Dual-ID assay were completely concordant for all clinical isolates (100%, 95% CI 98.56–100%). Out of 223 M. tuberculosis (MTB) isolates, 196 were pan-susceptible and 27 were resistant to RIF according to QMAP results. All of the mutations in the RIF resistance-determining region detected by the QMAP system were confirmed by rpoB sequence analysis and a REBA MTB-Rifa reverse blot hybridization assay. The majority of the mutations (n = 26, 96.3%), including those missing wild-type probe signals, were located in three codons (529–534, 524–529, and 514–520), and 17 (65.4%) of these mutations were detected by three mutation probes (531TTG, 526TAC, and 516GTC). Conclusions The entire QMAP system assay takes about 3 h to complete, while results from the culture-based conventional method can take up to 48–72 h. Although improvements to the QMAP system are needed for direct respiratory specimens, it may be useful for rapid screening, not only to identify and accurately discriminate MTBC from NTM, but also to identify RIF-resistant MTB strains in positive culture samples. © 2017 The Authors


PubMed | Chungnam National University, Korea Research Institute of Bioscience and Biotechnology and Optipharm Inc.
Type: | Journal: Transgenic research | Year: 2016

Production of transgenic pigs for use as xenotransplant donors is a solution to the severe shortage of human organs for transplantation. The first barrier to successful xenotransplantation is hyperacute rejection, a rapid, massive humoral immune response directed against the pig carbohydrate GGTA1 epitope. Platelet activation, adherence, and clumping, all major features of thrombotic microangiopathy, are inevitable results of immune-mediated transplant rejection. Human CD39 rapidly hydrolyzes ATP and ADP to AMP; AMP is hydrolyzed by ecto-5-nucleotidase (CD73) to adenosine, an anti-thrombotic and cardiovascular protective mediator. In this study, we developed a vector-based strategy for ablation of GGTA1 function and concurrent expression of human CD39 (hCD39). An hCD39 expression cassette was constructed to target exon 4 of GGTA1. We established heterozygous GGTA1 knock-out cell lines expressing hCD39 from pig ear fibroblasts for somatic cell nuclear transfer (SCNT). We also described production of heterozygous GGTA1 knock-out piglets expressing hCD39 and analyzed expression and function of the transgene. Human CD39 was expressed in heart, kidney and aorta. Human CD39 knock-in heterozygous ear fibroblast from transgenic cloned pigs, but not in non-transgenic pigs cells. Expression of GGTA1 gene was lower in the knock-in heterozygous ear fibroblast from transgenic pigs compared to the non-transgenic pigs cell. The peripheral blood mononuclear cells (PBMC) from the transgenic pigs were more resistant to lysis by pooled complement-preserved normal human serum than that from wild type (WT) pig. Accordingly, GGTA1 mutated piglets expressing hCD39 will provide a new organ source for xenotransplantation research.


The present invention relates to a Korean-type porcine reproductive and respiratory syndrome virus (PRRSV) and a vaccine composition using the same, and a method for preventing porcine reproductive and respiratory syndrome. Korean-type porcine reproductive and respiratory syndrome virus with accession number KCTC 12096BP according to the present invention is Korean-type porcine reproductive and respiratory syndrome virus distinguished from European strains and North American strains, and a vaccine composition specific to Korean-type porcine reproductive and respiratory syndrome virus is produced, thereby preventing a Korean-type porcine reproductive and respiratory syndrome virus or specifically diagnosing the infection with Korean-type porcine reproductive and respiratory syndrome virus.


Patent
Optipharm. Co. and Yonsei University | Date: 2013-12-05

There are provided an improved cervical cancer diagnosing method and a diagnostic kit for same. According to the present invention, it is possible to more rapidly and accurately provide a patient group requiring a clinical treatment and a prevention treatment in terms of a technical aspect to predict that the limitation of the existing HPV DNA test method can be overcome, automate the RNA extraction from eliminated cells, and more rapidly provide more objective and accurate results because the result analysis can be performed by software by using the real-time RT-PCR.


The present invention relates to a Korean-type porcine reproductive and respiratory syndrome virus (PRRSV) and a vaccine composition using the same, and a method for preventing porcine reproductive and respiratory syndrome. Korean-type porcine reproductive and respiratory syndrome virus with accession number KCTC 12096BP according to the present invention is Korean-type porcine reproductive and respiratory syndrome virus distinguished from European strains and North American strains, and a vaccine composition specific to Korean-type porcine reproductive and respiratory syndrome virus is produced, thereby preventing a Korean-type porcine reproductive and respiratory syndrome virus or specifically diagnosing the infection with Korean-type porcine reproductive and respiratory syndrome virus.


There are provided a method for an early diagnosis and a screening test for a therapeutic agent of breast cancer by using tissue and blood, and a quantitative reverse transcription polymerase chain reaction kit for same. According to the present invention, it is possible to provide help in more effective treatment and diagnosis of breast cancer through expression rates of HER2 expressed in blood and a cancer-related marker in the blood in addition to a tissue specimen.


PubMed | Yonsei University and Optipharm Inc.
Type: | Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | Year: 2016

Rapid and accurate identification of the causative pathogens of bloodstream infections (BSIs) is crucial for initiating an appropriate antimicrobial therapy which decreases the related morbidity and mortality rates. The aim of this study was to evaluate the usefulness of a newly developed multiplexed, bead-based bioassay system [i.e., the Quantamatrix Multiplexed Assay Platform (QMAP)], obtained directly from blood culture bottles, to simultaneously detect the presence of bacteria and identify the genes for antibiotic resistance.The QMAP system was used to evaluate 619 blood culture bottles from patients with BSIs and to compare the results of conventional culture methods.Using conventional bacterial cultures as the gold standard, the sensitivity, specificity, positive predictive value, and negative predictive value of the QMAP system for the detection of bacterial pathogens in positive blood culture (PBC) samples were 99.8% (n = 592, 95% CI 0.9852-1.000, p < 0.001), 100% (95% CI 0.983-1.000, p < 0.001), 100% (95% CI 0.9922-1.000, p < 0.001), and 99.5% (95% CI 0.9695-1.000, p < 0.001), respectively. In addition, sensitivity and specificity of the QMAP system for the identification of the genes for antibiotic resistance were 99.4% (n = 158, 95% CI 0.9617-0.9999, p < 0.009) and 99.6% (95% CI 0.9763-0.9999, p < 0.0001), respectively.Obtaining results using the QMAP system takes about 3 h, while culture methods can take up to 48-72 h. Therefore, analysis using the QMAP system is rapid and reliable for characterizing causative pathogens in BSIs.


PubMed | Ministry of Food & Drug Safety and Optipharm Inc.
Type: Journal Article | Journal: Clinical and experimental vaccine research | Year: 2016

Various new technologies have been applied for developing vaccines against various animal diseases. Virus-like particle (VLP) vaccine technology was used for manufacturing the porcine circovirus type 2 and RNA particle vaccines based on an alphavirus vector for porcine epidemic diarrhea (PED). Although VLP is classified as a killed-virus vaccine, because its structure is similar to the original virus, it can induce long-term and cell-mediated immunity. The RNA particle vaccine used a Venezuela equine encephalitis (VEE) virus gene as a vector. The VEE virus partial gene can be substituted with the PED virus spike gene. Recombinant vaccines can be produced by substitution of the target gene in the VEE vector. Both of these new vaccine technologies made it possible to control the infectious disease efficiently in a relatively short time.

Loading Optipharm Inc. collaborators
Loading Optipharm Inc. collaborators